Molecular principles underlying hepatitis C virus diagnosis

Although the rate of new cases of HCV infection has decreased as a result of public health policies related to intravenous drug users, the overall rate of infection in the U.S. is still high. With an estimated 3.9 million people infected nationwide, combined with the observation that, for over 50% of all cases of HCV infection, a route of infection is unknown, HCV will continue to be a major cause of infectious disease related morbidity and mortality for years to come. The benefit of molecular assays resides in providing for more effective treatment of HCV-infected patients, which will certainly justify the expense.